Preparation and biological evaluation of BACE1 inhibitors: Leveraging trans-cyclopropyl moieties as ligand efficient conformational constraints.Winneroski, L.L., Erickson, J.A., Green, S.J., Lopez, J.E., Stout, S.L., Porter, W.J., Timm, D.E., Audia, J.E., Barberis, M., Beck, J.P., Boggs, L.N., Borders, A.R., Boyer, R.D., Brier, R.A., Hembre, E.J., Hendle, J., Garcia-Losada, P., Minguez, J.M., Mathes, B.M., May, P.C., Monk, S.A., Rankovic, Z., Shi, Y., Watson, B.M., Yang, Z., Mergott, D.J.
(2020) Bioorg Med Chem 28: 115194-115194
- PubMed: 31786008
- DOI: 10.1016/j.bmc.2019.115194
- Primary Citation of Related Structures:
6UVP, 6UVV, 6UWP, 6UWV, 6UVY
- PubMed Abstract:
Inhibition of BACE1 has become an important strategy in the quest for disease modifying agents to slow the progression of Alzheimer's disease. We previously reported the fragment-based discovery of LY2811376, the first BACE1 inhibitor reported to dem ...
Inhibition of BACE1 has become an important strategy in the quest for disease modifying agents to slow the progression of Alzheimer's disease. We previously reported the fragment-based discovery of LY2811376, the first BACE1 inhibitor reported to demonstrate robust reduction of human CSF Aβ in a Phase I clinical trial. We also reported on the discovery of LY2886721, a potent BACE1 inhibitor that reached phase 2 clinical trials. Herein we describe the preparation and structure activity relationships (SAR) of a series of BACE1 inhibitors utilizing trans-cyclopropyl moieties as conformational constraints. The design, details of the stereochemically complex organic synthesis, and biological activity of these BACE1 inhibitors is described.
Lilly Research Laboratories, A Division of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA. Electronic address: firstname.lastname@example.org.